Biopharma · FDA Approvals · Stock

RNAC Cartesian Therapeutics

Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering cell therapy for the treatment of autoimmune diseases. The company uses technology and a manufacturing platform to introduce mRNA into cells to provide a therapeutic effect to patients suffering from a variety of autoimmune conditions. …

Assets on file: Descartes-08

Start live analysis of RNAC Run 8-agent AI analysis All sector events →

Catalyst calendar

Dated catalysts for RNAC, including recently decided ones.

December 2026

Dec 2026

Dec 1, 2026

in 31 days

RNACCartesian Therapeutics

Descartes-08: Phase 2 trial NCT06038474 expected to finish collecting primary-endpoint data (topline results usually follow)

Trial primary completionClinicalTrials.gov

Dec 2026

Dec 30, 2026

in 60 days

RNACCartesian Therapeutics

Descartes-08: Phase 3 trial NCT06799247 expected to finish collecting primary-endpoint data (topline results usually follow)

Trial primary completionClinicalTrials.gov

January 2027

Quarter only

~ Quarter only

RNACCartesian Therapeutics

Cartesian Therapeutics Reports Retreatment Data for Descartes-08 in MG at AANEM 2026

Trial readoutSEC 8-KQuarter only

November 2027

Nov 2027

~ Nov 2027

RNACCartesian Therapeutics

Descartes-08: Phase 2 trial NCT07391605 expected to finish collecting primary-endpoint data (topline results usually follow)

Trial primary completionClinicalTrials.govMonth only

December 2027

Dec 2027

~ Dec 2027

RNACCartesian Therapeutics

Descartes-08: Phase 1/Phase 2 trial NCT07089121 expected to finish collecting primary-endpoint data (topline results usually follow)

Trial primary completionClinicalTrials.govMonth only

Recent first-hand events

Every first-hand event for RNAC, newest first.

Instant stream — events appear as soon as they are filed.

Decision-gradeMaterialNotableMinor

Sep 29, 2026

11:33 AM

RNACCartesian Therapeutics

Cartesian Therapeutics Reports Retreatment Data for Descartes-08 in MG at AANEM 2026

Cartesian presented new retreatment data from five patients showing sustained MG-ADL reduction of 6.6 points and MGC reduction of 15 points at 12 months after a second course of Descartes-08, with median retreatment at 16.6 months and no new safety signals. The company reiterated that topline data from the Phase 3 AURORA trial in generalized myasthenia gravis is expected in 1Q 2027, with BLA filing planned for mid-2027.

Conference presentationSEC 8-K

Nov 13, 2025

09:08 PM

RNACCartesian Therapeutics

Cartesian reports 100% LLDAS response in Phase 2 SLE trial of Descartes-08

Phase 2 open-label data show 100% LLDAS response and 2/3 DORIS remission at Month 3 in refractory SLE patients treated with outpatient Descartes-08. The company will pause further SLE development to prioritize myasthenia gravis (Phase 3) and myositis (Phase 2 trial planned to start 1H26).

Topline resultsSEC 8-K Open record2 updates